Skip to content
stoqly

Neogenomics Inc

NEO Nasdaq Services-Testing Laboratories Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$727M
10.1% vs prior year
Operating margin Operating income as a share of revenue.
−15.9%
2.0 pts
Net income Profit after all expenses, interest and tax.
−$108M
Free cash flow Cash from operations minus capital spending.
−$21.8M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−9.0%
2.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—

What Neogenomics Inc does

No business description yet.

Legal name
NEOGENOMICS INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 17, 2026
Accession · CIK
0001077183-26-000010
0001077183

Revenue and margins

Neogenomics Inc had $727M of revenue in fiscal 2025, up 10.1% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$21.8M in fiscal 2025, −3.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Neogenomics Inc returned — to shareholders in fiscal 2025. The diluted share count rose 1.1%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Neogenomics Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $515M$263M$342M$367M$160M
Debt incl. finance leases $534M$535M$538M$541M$342M
Debt / equity 0.5x0.5x0.6x0.6x0.4x
Interest coverage −14.4x−20.8x−15.6x−13.9x−30.9x
Current ratio 7.8x6.7x6.2x2.0x4.3x
Quick ratio 7.5x6.5x5.9x1.9x3.9x
Total assets $1.9B$1.7B$1.7B$1.6B$1.4B
Total liabilities $762M$742M$740M$736M$523M
Shareholders' equity $1.1B$998M$942M$902M$837M
Net debt (− = net cash) $18.3M$272M$196M$174M$182M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✓ ✓
Return on assets rose — ✓ ✓ ✓ ✕ ✕ ✕ ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✕ ✕ ✓ ✓ ✓ ✓
Debt fell relative to assets — ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓
Current ratio rose — ✓ ✕ ✓ ✓ ✓ ✕ ✕ ✕ ✓
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — ✓ ✓ ✓ ✕ ✕ ✕ ✓ ✓ ✕
Revenue rose relative to assets — ✓ ✕ ✓ ✕ ✕ ✓ ✓ ✓ ✓
F-score — / 37 / 96 / 98 / 93 / 91 / 92 / 94 / 95 / 95 / 9
Accruals ratio −8.2%−5.4%−9.9%−2.5%0.3%1.3%−4.3%−5.0%−5.2%−7.6%
Altman Z'' 1.461.742.394.804.853.162.452.381.441.46

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $232M $240M $277M $409M $444M $484M $510M $592M $661M $727M
Net interest income $10.0M $5.5M — — — — — — — —
Gross profit $98.1M $102M $127M $197M $186M $187M $188M $245M $290M $314M
Research and development $4.6M $3.6M $3.0M $8.5M $8.2M $21.9M $30.3M $27.3M $31.2M $37.1M
Operating income $2.2M $2.9M $10.0M $13.0M −$14.0M −$119M −$158M −$108M −$92.1M −$116M
Interest expense — $5.5M $6.2M $3.7M $7.0M $8.2M $7.6M $6.9M $6.6M $3.8M
Pretax income −$7.8M −$2.7M $3.8M $3.6M −$14.1M −$15.1M −$159M −$97.1M −$80.7M −$110M
Income tax −$1.7M −$2.3M $1.2M −$4.4M −$18.2M −$6.7M −$15.1M −$9.1M −$1.9M −$2.2M
Net income −$6.1M −$0.4M $2.6M $8.0M $4.2M −$8.3M −$144M −$88.0M −$78.7M −$108M
Net income to common −$30.8M −$10.9M $6.1M $8.0M $4.2M −$8.3M −$144M −$88.0M −$78.7M —
Diluted shares 0.08B 0.08B 0.09B 0.10B 0.11B 0.12B 0.12B 0.13B 0.13B 0.13B
Cash flow
Cash from operations $21.5M $18.0M $44.8M $23.4M $1.5M −$26.7M −$66.0M −$2.0M $7.0M $5.2M
Capital expenditure $7.5M $13.7M $14.3M $20.0M $29.1M $64.1M $30.9M $28.8M $41.1M $27.0M
Free cash flow $13.9M $4.3M $30.5M $3.3M −$27.6M −$90.9M −$96.9M −$30.7M −$34.0M −$21.8M
Depreciation and amortization $15.9M $15.6M $15.8M $20.3M $25.9M $30.2M $35.4M $37.5M $39.1M $36.1M
Stock-based compensation $5.4M $6.4M $7.0M $10.0M $10.2M $22.5M $24.7M $24.6M $33.4M $41.3M
Acquisitions −$1.0M $0.0M $125M $0.0M $37.0M $419M $0.0M $0.0M $0.0M $6.5M
Balance sheet
Cash and short-term investments $12.5M $12.8M $9.8M $173M $296M $515M $263M $342M $367M $160M
Total debt $97.9M $96.7M $102M $100M $169M $534M $535M $538M $541M $342M
Current assets $78.8M $85.9M $104M $291M $449M $682M $605M $597M $596M $376M
Current liabilities $38.1M $36.5M $60.9M $63.9M $73.2M $87.2M $89.9M $96.3M $301M $88.3M
Inventory $6.3M $7.5M $8.7M $14.4M $29.5M $23.4M $24.3M $24.2M $26.7M $28.6M
Property and equipment, net $34.0M $36.5M $60.9M $64.2M $85.9M $109M $102M $92.0M $94.1M $84.8M
Goodwill $147M $147M $198M $199M $211M $527M $523M $523M $523M $524M
Intangible assets $77.1M $74.2M $140M $127M $121M $442M $408M $373M $340M $287M
Total assets $337M $344M $505M $710M $988M $1.9B $1.7B $1.7B $1.6B $1.4B
Total liabilities $151M $140M $185M $202M $294M $762M $742M $740M $736M $523M
Shareholders' equity $162M $172M $320M $507M $694M $1.1B $998M $942M $902M $837M
Margins
Gross margin 42.3% 42.4% 46.0% 48.1% 41.8% 38.6% 36.9% 41.3% 43.9% 43.2%
Operating margin 0.9% 1.2% 3.6% 3.2% −3.1% −24.5% −30.9% −18.2% −13.9% −15.9%
EBITDA margin 7.8% 7.7% 9.3% 8.2% 2.7% −18.3% −24.0% −11.9% −8.0% −11.0%
Net margin −2.6% −0.2% 1.0% 2.0% 0.9% −1.7% −28.3% −14.9% −11.9% −14.9%
FCF margin 6.0% 1.8% 11.0% 0.8% −6.2% −18.8% −19.0% −5.2% −5.2% −3.0%
Net interest share of revenue 4.3% 2.3% — — — — — — — —
Returns
Return on capital 0.7% 0.9% 1.7% 3.0% −1.9% −8.3% −9.8% −7.5% −6.8% −9.0%
Return on capital employed 0.7% 0.9% 2.3% 2.0% −1.5% −6.7% −9.6% −6.8% −6.9% −9.1%
Return on equity −3.8% −0.2% 1.1% 1.9% 0.7% −0.9% −13.7% −9.1% −8.5% −12.4%
Return on assets −1.8% −0.1% 0.6% 1.3% 0.5% −0.6% −8.0% −5.1% −4.7% −7.2%
Return on tangible equity — — — 4.4% 1.2% −6.0% −215.3% −192.7% −197.3% −420.5%
Growth
Revenue growth — 3.6% 15.2% 47.7% 8.7% 9.0% 5.2% 16.1% 11.6% 10.1%
Net income growth — — — 203.3% −47.9% −300.1% — — — —
FCF growth — −68.8% 601.1% −89.0% −927.4% — — — — —
Share count change — 2.4% 15.3% 13.2% 7.9% 7.3% 3.5% 1.0% 0.9% 1.1%
Financial health
Net debt / EBITDA 4.7x 4.5x 3.6x −2.2x −10.7x — — — — —
Debt / equity 0.6x 0.6x 0.3x 0.2x 0.2x 0.5x 0.5x 0.6x 0.6x 0.4x
Interest coverage — 0.5x 1.6x 3.5x −2.0x −14.4x −20.8x −15.6x −13.9x −30.9x
Current ratio 2.1x 2.4x 1.7x 4.5x 6.1x 7.8x 6.7x 6.2x 2.0x 4.3x
Quick ratio 1.9x 2.1x 1.6x 4.3x 5.7x 7.5x 6.5x 5.9x 1.9x 3.9x
Capital allocation
Capex / revenue 3.3% 5.7% 5.2% 4.9% 6.5% 13.2% 6.1% 4.9% 6.2% 3.7%
Stock comp / revenue 2.3% 2.7% 2.5% 2.4% 2.3% 4.6% 4.8% 4.2% 5.1% 5.7%
Quality scores
Piotroski F-score — 7.0 6.0 8.0 3.0 1.0 2.0 4.0 5.0 5.0
Altman Z'' 1.5 1.7 2.4 4.8 4.9 3.2 2.4 2.4 1.4 1.5
Accruals ratio −8.2% −5.4% −9.9% −2.5% 0.3% 1.3% −4.3% −5.0% −5.2% −7.6%

Source: SEC EDGAR XBRL filings (CIK 0001077183). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open